INTRODUCTION

Musculoskeletal system is one of the systems of human body which undergoes physiological changes with aging. Meanwhile, wear and tear of human tissues such as bone and muscle is another observed phenomenon of old age. Lumbar spine and neck of femur are most common sites affected in elderly by pathological process of Osteopenia.

Osteoarthritis (OA) is most common form of arthritis affecting people worldwide. This degenerative joint disease causes destruction of articular cartilage and synovial joints in elderly people. OA is characterized by joint pain, swelling, tenderness, stiffness, movement restriction, bone spurs and joint deformities. With advancement in diagnostics, a large number of aging population is diagnosed with OA leading to high impact on human quality of life.

OA is global economic burden on society due to increasing incidence and high economic cost. Currently multiple treatment strategies are in practice for OA. These are three fold i.e. non pharmacological e.g physical and rehabilitation therapy, exercise, massage and occupational therapy, pharmacological and surgical therapies in terms of joint replacement. Recently it has been observed that medicines with regenerating ability of human tissues are helpful in relieving OA symptoms and reversing tissue pathology. These drugs have shown promising results not only in reducing replacement surgeries but also played important role in palliation. Platelet rich plasma (PRP) is one of leading drug treatment options in treating early knee OA. It is obtained from autologous blood and is enriched with platelets and variety of growth factors. PRP accelerates healing of cartilage morphology in damaged joint by enhancing synovial cell proliferation and differentiation. Platelet rich plasma is one of regeneration therapy that reduces pain and promotes healing of degenerated tissues. PRP trials have been conducted for the treatment of osteoarthritis, including femoral head osteonecrosis, cartilage trauma and rheumatoid arthritis with promising outcome. It has already been claimed by Lee et al that PRP has beneficial role in treatment of rheumatoid arthritis with minimal side effects by inhibiting inflammatory process in involved joint synovial fluid. Many growth factors, bioactive molecules and cytokines in extracted PRP are an integral part of innovative treatment protocol. Moreover, efficiency of PRP was established by Sadabad et al for the treatment of knee osteoarthritis.

The rationale of this study was to make an assessment on the justification of the approach taken towards the use of intra-articular injection of platelet rich plas-
ma for the treatment of OA pain and define a new modality in chronic pain management for OA pain.

**METHODOLOGY**

This prospective observational study was conducted at Combined Military Hospital Rawalpindi, from August 2018 to January 2019 after approval from ethics committee/institutional review board (IRB) Ltr no: 07/ 04/62/20.

Sample size of 40 patients (20 patients in each group) is calculated by using 80% power of the test, 5% level of significance and incidence of patients with requirement of dexmedetomidine in first six hours postoperatively will be 40%.

- \( p1 = \text{probability population 1} = 40\% \\)
- \( p2 = \text{probability population 2} = 40\% \)
- \( Z = \text{confidence level} = 1.48 \)
- \( n = 40 \)

Sampling technique: non-probability convenience sampling.

After admission of patient in pain clinic, knee examination was conducted and grading of OA was done by Kellgren-Lawrence classification based on radiological features. After written informed consent patients with grade 1-3 were included in study. Patients with previous knee surgery, rheumatoid arthritis, hemophilia and on anticoagulants were excluded.

Standard monitoring including blood pressure, heart rate, pulse oximetry and electrocardiogram was attached to every patient in pain clinic. Under aseptic conditions 30ml of autologous blood was taken in pre dedicated centrifuge kits for obtaining platelet rich plasma. This sample was centrifuged for 20 minutes at 3200 rpm. The collected plasma was centrifuged again for 5 minutes at 1,500 rpm speed. Thus final 10mL of injectate solution, rich in platelets was prepared for intra-articular knee injection.

In procedure room, under sterile conditions, after administration of local anesthetics, 23 G spinal needle was inserted in knee joint. 1ml of dye (Omnipaque 350) was given and needle position confirmed under fluoroscopy. After confirmation of needle position 10ml of PRP solution was given under aseptic measures. Patients were kept under observation for 1 hour after procedure. Paracetamol tablets were advised if they feel post procedural pain.

Levels of knee pain were evaluated by numerical rating scale (fig-1) and recorded for every patient at specified time point, immediately before the first injection, after 3 weeks prior to second injection, at 6 weeks prior to third injection and 6 months later.

![Figure-1: Numerical rating scale.](image)

Data were extracted using mean ± SD for quantitative variables and frequency and percentage for qualitative ones. Analysis was made using prism graph pad software version 7. For quantitative variables, to measure significance t-test was applied. The \( p \)-value ≤0.05 was considered statistically significant.

**RESULTS**

In total, 40 patients were included which received PRP intra articular injection at different time intervals. The demographic characteristics of the patients are shown in table-I. The patients in the inclusion criteria did not differ significantly in terms of age and sex.

Figure-1 showed the numeric pain scale (NRS) used in this study and value of NRS at different times intervals was shown in table-I. The value of pain score in patients included in the study according to the NRS criteria was shown in table-II. The patients suffered from knee arthritis showed severe pain which was 8.1 on NRS criteria. However, after intra articular injection of PRP at different time intervals there was significant decrease in pain score. At third week of PRP injection, NRS score was 5.4 which was significantly less than NRS value before PRP injection (\( p=0.33 \)). In the comparison of NRS between different time intervals of PRP injection, there was significantly less NRS score at 6th

![Table-I: Value of NRS at different times intervals.](image)

<table>
<thead>
<tr>
<th>Time Interval</th>
<th>NRS Value before PRP</th>
<th>NRS Value at 1st injection</th>
<th>NRS Value at 2nd injection</th>
<th>NRS Value at 3rd injection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before PRP</td>
<td>8.1</td>
<td>5.4</td>
<td>3.7</td>
<td>2.3</td>
</tr>
<tr>
<td>1st Week</td>
<td>8.1</td>
<td>5.4</td>
<td>3.7</td>
<td>2.3</td>
</tr>
<tr>
<td>2nd Week</td>
<td>8.1</td>
<td>5.4</td>
<td>3.7</td>
<td>2.3</td>
</tr>
<tr>
<td>3rd Week</td>
<td>8.1</td>
<td>5.4</td>
<td>3.7</td>
<td>2.3</td>
</tr>
</tbody>
</table>

**Table II: Numeric rating pain scale at different intervals.**

<table>
<thead>
<tr>
<th>Total number of patients</th>
<th>Before PRP</th>
<th>1st Week</th>
<th>2nd Week</th>
<th>3rd Week</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>8.1</td>
<td>5.4</td>
<td>3.7</td>
<td>2.3</td>
</tr>
</tbody>
</table>

- \( p \)-value = 0.26688

from knee arthritis showed severe pain which was 8.1 on NRS criteria. However, after intra articular injection of PRP at different time intervals there was significant decrease in pain score. At third week of PRP injection, NRS score was 5.4 which was significantly less than NRS value before PRP injection (\( p=0.33 \)). In the comparison of NRS between different time intervals of PRP injection, there was significantly less NRS score at 6th
week interval ($p=3.7$) as compared to 3rd week interval ($p=0.33$). However, more pronounced effect was observed at 6th month of PRP injection which showed the significant reduction in pain score (2.3) as compared to 3rd and 6th week interval ($p=0.44$) indicating the prolonged effect of PRP after intra articular knee injection in OA as shown in fig-2.

![Figure-2: Graphical representation of statistical analysis.](image)

**DISCUSSION**

Degenerative joint diseases are sequel of aging. Knee joint OA is one of common disease among them. Previously for knee OA multiple treatment modalities including invasive and non-invasive have been tried. Primary treatment for knee OA is analgesics proceeded by Physical and rehabilitation therapy. Intra-articular injection of hyaluronic acid and corticosteroids have been tried as second line of treatment. Platelet rich plasma (PRP), prolotherapy (PRL), and radiofrequency ablation (RFA) are next step in treatment modality. Surgical intervention in form of joint replacement is last resort but with its own complications in this age group. Recent studies have shown significant improvements in patient-reported symptoms with results favoring PRP over Hyaluronic acid. Many studies have ascertained beneficial role of PRP therapy in minimizing pain and symptoms of OA.

Each ml of platelet rich plasma solution contain approximately 1-2 million platelets and variety of growth factors. Upon activation platelets release multiple substances including growth factors and cytokines. These substances are involved in increased proliferation and differentiation of chondrocytes. Furthermore, PRP also inhibits NF-κB pathway for its anti-inflammatory effects.

This study proved that platelet rich plasma therapy reduced pain and improved functional capacity of knee OA patients for up to 6 months. Although the treated patients observed decrease in pain in progressive fashion up to six weeks after therapy, however maximum benefit was seen up to 6 months in pain relief and functional ability. Platelet rich plasma therapy is safe and cost effective in short term symptomatic relief in knee osteoarthritis. The degree of knee OA is an important factor to determine the efficacy of platelet rich plasma injection and duration of symptoms relief. PRP therapy has shown good results in young population at early stage of disease.

Duymus et al observed that patients with mild to moderate knee OA experienced better pain relief and pain free daily activities up to 12 months, when treated with Platelet rich plasma as compared to Hyaluronic acid and Ozone injections.

Intra-articular injection of PRP results in reduction of significant degenerative articular inflammatory changes. Himanshu et al concluded that Mean synovial fluid cartilage oligomeric matrix protein concentration was dramatically less in platelet rich plasma therapy treated patients. They also observed decreased synovial vascularity and synovitis in these patients at three and six months interval. Wen et al compared effects of platelet rich plasma, Hyaluronic acid and saline in affected OA knees. They come up with conclusion that intra-articular Platelet rich plasma injection may be more beneficial in pain relief and functional improvement in symptomatic patients at 1 year post injection interval. Investigators observed a remarkable difference between platelet rich plasma and hyaluronic acid groups of patients in terms of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores. Patients with PRP therapy showed better functional scores. In a systematic review, the results were favorable for platelet rich plasma intervention as compared to NSAIDs, hyaluronic acid and corticosteroids in symptomatic knee OA up to 12 months. Deficiency of growth hormone is another important factor in determining the severity of articular cartilage pathology in Knee OA. This study proved that platelet rich plasma therapy is more useful in osteoarthritic knee patients whose condition has not been improved by conventional treatment.

Lack of morphological assessment of knee joint, small sample size and limited time frame are some limitations of this study.

**CONCLUSION**

Platelet rich plasma is simple, cost effective and less invasive therapy for treatment of knee joint degenerative lesions. Platelet rich plasma therapy also has important role in improving functional outcome and
alleviating pain of knee OA. This study, proved beneficial role of Platelet rich plasma in decreasing pain and functional limitations in knee OA patients up to 6 months of follow-up. Platelet rich plasma intervention for knee joint OA has minimal side effects.

For better understanding of mechanism of action and measure outcome of platelet rich plasma, well designed randomized controlled trials are essential.

CONFLICT OF INTEREST

This study has no conflict of interest to be declared by any author.

REFERENCES


